Compare Cadence Design Systems Inc (CDNS) vs Crispr Therapeutics AG (CRSP) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cadence Design Systems Inc vs Crispr Therapeutics AG — how do they compare? Cadence Design Systems Inc trades at $331.62 (market cap $90.20B), while Crispr Therapeutics AG trades at $54.59 (market cap $5.23B). The key difference: Cadence Design Systems Inc is far larger — about 17.2× Crispr Therapeutics AG's market cap, and Cadence Design Systems Inc is trading nearer its 52-week high, Crispr Therapeutics AG nearer its low. Which is the better fit depends on your goals.
| CDNS | CRSP | |
|---|---|---|
Market Cap | $90.20B | $5.23B |
Sector | Technology | Health |
52-Week High | $416.39 | $76.78 |
52-Week Low | $265.66 | $44.34 |
Enterprise Value | $91.41B | $3.65B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Cadence Design Systems (CDNS) trades at $331.91, down 2.16% amid a bearish technical signal, though it remains supported by strong fundamentals. The company reported Q2 2026 earnings that beat estimates, with revenue growth of 24.2% driven by AI demand, and raised its full-year outlook. Analyst consensus is strongly bullish with an average price target of $415.11, representing 25% upside potential from current levels.
The stock offers compelling growth prospects from AI-driven semiconductor design demand, with record backlog of $8.1 billion supporting future revenue visibility. Key risks include high valuation multiples (P/E 65.12) and potential semiconductor cycle volatility. Institutional ownership remains strong with recent position increases by major funds like Amundi.
CRISPR Therapeutics (CRSP) trades at $53.51, down slightly by 0.02% today. The stock shows bullish technical signals with strong support at $53 and resistance at $54. Fundamentally, the company reports widening losses with a net income margin of -4,101.26% in 2025, though Q2 2026 earnings beat expectations. Analyst sentiment remains positive with a consensus price target of $82.67, driven by robust CASGEVY sales growth and pipeline advancements.
Outlook: CRSP offers significant upside potential from gene-editing therapeutics, but high cash burn and negative profitability pose risks. Investment appeal hinges on successful clinical trials and market expansion of approved therapies, balanced against financial sustainability concerns in a competitive biotech landscape.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Cadence Design Systems Inc
Cadence Design Systems is a provider of electronic design automation software, intellectual property, and system design and analysis products. EDA software automates the chip design process, enhancing design accuracy, productivity, and complexity in a full-flow end-to-end solution. Cadence offers a portfolio of design IP, as well as system design and analysis products, which enable system-level analysis and verification solutions. Cadence's comprehensive portfolio is benefiting from a mutual convergence of semiconductor companies moving up-stack toward systems-like companies, and systems companies moving down-stack toward in-house chip design. The resulting expansion in EDA customers, alongside secular digitalization of various end markets, benefits EDA vendors like Cadence.
Read more on CDNS →About Crispr Therapeutics AG
CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR's most advanced pipeline candidate, CTX001, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.
Read more on CRSP →
